DNLI Denali Therapeutics Inc.
8-K Current Report
Filed: February 26, 2026
Health Care
Biological Products, (No Diagnostic Substances)Denali Therapeutics Inc. (DNLI) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 2.02: Results of Operations and Financial Condition
AI Filing Analysis8-K
Item 2.02 · Results of Operations and Financial Condition
- • Q4 2025 earnings press release issued Feb 26, 2026 — full financial results in Exhibit 99.1
- • Key figures (revenue, cash, pipeline metrics) not disclosed in filing body — refer to attached press release for details
Other Denali Therapeutics Inc. 8-K Filings
Get deeper insights on Denali Therapeutics Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.